Literature DB >> 228555

Establishment and characterization of a new endometrial cancer cell line (SCRC-1).

J Gorodecki, R Mortel, R L Ladda, S P Ward, L Geder, F Rapp.   

Abstract

A new human endometrial cell line, SCRC-1, has been established from a uterine adenocarcinoma. During a period of 57 weeks in culture, the SCRC-1 cells have been passaged over 100 times. Cultures have an epitheloid morphology, high mitotic activity, and a tendency to form multiple cell layers. The cells are polygonal and are arranged in pavement-like fashion. Most have multiple nucleoli, some are multinucleated, and all have heavily vacuolated cytoplasm. Pretreatment with iododeoxyuridine did not reveal viral markers by cocultivation or immunofluorescence techniques. Karyologic studies indicate that the SCRC11 cell line is essentially diploid with a small subpopulation of tetraploid cells. Over a period of 20 weeks, 1 of 14 athymic nude mice inoculated with SCRC-1 cells developed a tumor which histologically closely resembled the original human tumor. Cells were subsequently propagated from this tumor and the resulting epitheloid-like cell line was designated SCRC-1, Tu 1.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 228555     DOI: 10.1016/s0002-9378(16)32994-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

1.  Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture.

Authors:  D L Way; D S Grosso; J R Davis; E A Surwit; C D Christian
Journal:  In Vitro       Date:  1983-03

2.  Growth, morphologic, and invasive characteristics of early and late passages of a human endometrial carcinoma cell line (RL95-2).

Authors:  P Sundareshan; M J Hendrix
Journal:  In Vitro Cell Dev Biol       Date:  1992 Jul-Aug

3.  The EnDA endometrial adenocarcinoma: an oestrogen-sensitive, metastasizing, in vivo tumour model of the rat.

Authors:  D W Horn; G Vollmer; F Deerberg; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.